Brain Edema - Pipeline Review, H1 2016

  • ID: 3766786
  • Report
  • 44 pages
  • Global Markets Direct
1 of 5
Brain Edema - Pipeline Review, H1 2016

Summary

The report ‘Brain Edema - Pipeline Review, H1 2016’, provides an overview of the Brain Edema pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Brain Edema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Brain Edema and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Brain Edema
- The report reviews pipeline therapeutics for Brain Edema by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Brain Edema therapeutics and enlists all their major and minor projects
- The report assesses Brain Edema therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Brain Edema

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Brain Edema
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Brain Edema pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5
List of Tables

List of Figures

Introduction

Report Coverage

Brain Edema Overview

Therapeutics Development

Pipeline Products for Brain Edema - Overview

Pipeline Products for Brain Edema - Comparative Analysis

Brain Edema - Therapeutics under Development by Companies

Brain Edema - Therapeutics under Investigation by Universities/Institutes

Brain Edema - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Brain Edema - Products under Development by Companies

Brain Edema - Products under Investigation by Universities/Institutes

Brain Edema - Companies Involved in Therapeutics Development

FibroGen, Inc.

Pharmazz, Inc.

Remedy Pharmaceuticals, Inc.

Brain Edema - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

AER-271 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Drugs to Modulate Aquaporin Channels for Brain Edema and Cancer - Drug Profile

Product Description

Mechanism of Action

R&D Progress

FG-4497 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

glyburide - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PMZ-2123 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Block Aquaporin-4 for Brain Edema - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Brain Edema - Recent Pipeline Updates

Brain Edema - Dormant Projects

Brain Edema - Product Development Milestones

Featured News & Press Releases

Apr 11, 2016: Remedy Pharmaceuticals Announces Two Oral Presentations on Results of CNS-Related Edema Trial At Annual American Academy of Neurology Meeting

Apr 06, 2016: Remedy Pharmaceuticals Issues First Quarter 2016 Report

Mar 04, 2016: Remedy Pharmaceuticals Announces Successful Completion of End-of-Phase 2 Meeting With FDA on a Novel Drug Treatment for CNS-Related Edema

Feb 22, 2016: Remedy Pharmaceuticals Announces Additional Results From Phase 2 CNS-Related Edema Study of CIRARA Presented at International Stroke Conference

Feb 08, 2016: Remedy Pharmaceuticals Announces Acceptance of Two Oral Presentations on Phase 2 Results of CIRARA for CNS-Related Edema at ISC 2016

Jan 05, 2016: CNS-Related Edema Company Remedy Pharmaceuticals Strengthens Leadership Team in Preparation for Phase 3 Trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Brain Edema, H1 2016

Number of Products under Development for Brain Edema - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Brain Edema - Pipeline by FibroGen, Inc., H1 2016

Brain Edema - Pipeline by Pharmazz, Inc., H1 2016

Brain Edema - Pipeline by Remedy Pharmaceuticals, Inc., H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Brain Edema Therapeutics - Recent Pipeline Updates, H1 2016

Brain Edema - Dormant Projects, H1 2016

List of Figures

Number of Products under Development for Brain Edema, H1 2016

Number of Products under Development for Brain Edema - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Targets, H1 2016

Number of Products by Stage and Targets, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
FibroGen, Inc.
Pharmazz, Inc.
Remedy Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll